Yungjin Pharm (CEO: Chae J. Lee) has announced that the company has signed the Collaborative Research Agreement with Neuramedy (CEO: Seung-jae Lee, Min-sub Lee) on the 16^th of October.

Under this Agreement, both of the company will collaborate on the research to venture the small molecule candidate that will regulate the alpha-synuclein aggregation, which is known as the cause of the Parkinson’s disease.

Alpha-synuclein is a protein that plays a key role in the development and progression of various neurodegenerative diseases, including Parkinson's disease. It is known to destroy nerve cells through abnormal aggregation and deposition.

Prior to the Agreement, the two companies announced that they have arrived at the hit compound acquisition of alpha-synuclein mechanism through basic research. On the basis of this acquisition, Yungjin Pharm will be in charge of Lead Optimization of new drug development, while Neuramedy will be in charge of verification of its activity and its efficacy with the expertise in the drug assessment related to Parkinson's disease.

“This agreement is the part of the open innovation (oncology drugs, CNS and rare diseases) strategy of Yungjin Pharm” mentioned Chae J. Lee, Yungjin’s CEO, and “this will strengthen our innovative new drug pipeline and it will lay the foundation for Yungjin Pharm to become a global pharmaceutical company”.

Meanwhile, Neuramedy was established in 2019 with the aim of developing treatments and diagnostic products for neurodegenerative diseases, including Parkinson's disease. Recently, they adapted the Parkinson's disease antibody drug (TLR2 antibody) as part of the pipeline.